Results 71 to 80 of about 65,500 (223)

Reactive Infectious Mucocutaneous Eruption (RIME): An Australian Case Series

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Whilst Reactive Infectious Mucocutaneous Eruption (RIME) displays a low mortality rate, the condition results in significant morbidity and resource allocation, including prolonged hospital admission. As such, early diagnosis and optimisation of treatment is imperative.
Hamish Moore, Emma Ryan, Annabel Stevenson   +2 more
wiley   +1 more source

Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves [PDF]

, 2015
peer-reviewedBackground There is a need to improve vaccination against respiratory pathogens in calves by stimulation of local immunity at the site of pathogen entry at an early stage in life. Ideally such a vaccine preparation would not be inhibited by
A Menanteau-Horta, A Vila, AR Peters, B Morein, B Morein, Bernadette Earley, BJF Bradshaw, BM Adair, Bryan Markey, C Pilette, CA Siegrist, CX Song, DG Bryson, DP Greenberg, EM Liebler-Tenorio, F Alexis, F Mansoor, Fawad Mansoor, FM Buonaguro, HM Chen, I Vangeel, J Phillips, J Pollock, JE Crowe, Joseph P. Cassidy, JS Salt, K Tahara, KJ Wiechelman, M Garinot, M Higaki, Michael D. Welsh, ML Hans, MS Lee, OV Kavanagh, PE Shewen, PK Smith, PR Wood, RE Brown, RM Zinkernagel, S Lofthouse, Simon Doherty, TG Kimman, YJ Kwon   +42 more
core   +1 more source

Treosulfan–fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study

British Journal of Haematology, EarlyView.
Summary Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for severe combined immunodeficiency (SCID). Conditioning improves donor engraftment and freedom from immunoglobulin replacement (IgR) but increases the risks of acute and late toxicity. Treosulfan, a reduced toxicity alkylating agent, has emerged as an alternative
Su Han Lum, Sinéad Greener, Irum Latif Memon, Persis Amrolia, Zohreh Nademi, Robert Chiesa, Juliana Silva, Helen Young, Stephen Owens, Eleri Williams, Khuen Foong Ng, Terry Flood, Andrew R Gennery, Sophie Hambleton, Kanchan Rao, Mary Slatter   +15 more
wiley   +1 more source

Inhibition of human parainfluenza virus type 3 infection by novel small molecules [PDF]

Antiviral Research, 2008
Human parainfluenza virus type 3 (HPIV3) is an important respiratory tract pathogen of infants and children. There are no vaccines or antivirals currently approved for prevention or treatment of HPIV3 infection. Towards developing an antiviral therapy to combat HPIV3 infection, we have established a green fluorescent protein (GFP)-tagged HPIV3 infected-
Hongxia, Mao, Chandar S, Thakur, Santanu, Chattopadhyay, Robert H, Silverman, Andrei, Gudkov, Amiya K, Banerjee   +5 more
openaire   +2 more sources

Cross-protective antibodies against common endemic respiratory viruses

Nature Communications, 2023
Respiratory syncytial virus (RSV), human metapneumovirus (HMPV), and human parainfluenza virus types one (HPIV1) and three (HPIV3) can cause severe disease and death in immunocompromised patients, the elderly, and those with underlying lung disease.
Madelyn Cabán, Justas V. Rodarte, Madeleine Bibby, Matthew D. Gray, Justin J. Taylor, Marie Pancera, Jim Boonyaratanakornkit   +6 more
doaj   +1 more source

Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3. [PDF]

Rev Med Virol
ABSTRACT Human parainfluenza virus‐type 3 (HPIV3) is a respiratory virus responsible for mild illnesses in most of the population and severe illnesses, such as bronchiolitis and pneumonia, in young children, immunocompromised individuals and the elderly.
Vacher C, Dubois J, Hamelin ME, Boivin G, Rosa-Calatrava M.   +4 more
europepmc   +2 more sources

Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future [PDF]

, 2014
Serological techniques commonly used to quantify influenza-specific antibodies include the Haemagglutination Inhibition (HI), Single Radial Haemolysis (SRH) and Virus Neutralization (VN) assays.
Callow, Calza, Chan, Cosma, De Jong, Farrohi, Ferrara, Fox, Frank, Fulton, Gross, Halloran, Harmon, Hierholzer, Johansson, Johansson, Kendal, Kilbourne, Montomoli, Okuno, O’Neill, Powers, Probert, Rowe, Schild, Schulman, Schulman, Scott, Sylte, Van Assen, Yewdell   +30 more
core   +3 more sources

Infection Complications in Pediatric Patients With Inborn Errors of Immunity After Umbilical Cord Blood Transplantation: A Chinese Single‐Center Study

Transplant Infectious Disease, EarlyView.
This study reveals that infections are highly prevalent in pediatric IEI patients after umbilical cord blood transplantation, with early‐stage infections and bloodstream infections strongly associated with poorer survival. These findings advocate for risk‐stratified surveillance and preemptive strategies in high‐risk subgroups.
Zhongling Wei, Ping Wang, Wenjin Jiang, Jie Man, Ying Huang, Xiaochuan Wang, Hongsheng Wang, Xiaowen Qian, Xiaowen Zhai   +8 more
wiley   +1 more source

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous–venous extracorporeal membrane oxygenation (VV‐ECMO): A case report

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1487-1492, May 2026.
While providing potentially life‐saving cardiorespiratory support for critically ill patients, extracorporeal membrane oxygenation (ECMO) may detrimentally affect pharmacokinetic (PK) performance and concurrent drug efficacy and safety. We describe a patient with Pneumocystis jirovecii pneumonia (PJP) in the context of acquired immunodeficiency ...
Tom C. Zwart, Emiel Leegwater, Thomas H. Ottens, Emile F. Schippers, Erik B. Wilms, David M. Burger, Cees van Nieuwkoop, Liesbeth B. E. Bosma   +7 more
wiley   +1 more source

Impact of COVID‐19 on Respiratory Virus Infections in Children, Japan, 2018–2023

Immunity, Inflammation and Disease
Background COVID‐19, caused by SARS‐CoV‐2, was first documented in Japan in January 2020. We previously reported an increased risk of rhinovirus infections among children during the early phase of the COVID‐19 pandemic.
Emi Takashita, Kohei Shimizu, Chiharu Kawakami, Tomoko Momoki, Miwako Saikusa, Hiroki Ozawa, Makoto Kumazaki, Shuzo Usuku, Nobuko Tanaka, Ryuichi Senda, Ichiro Okubo, Seiichiro Fujisaki, Shiho Nagata, Hiroko Morita, Hideka Miura, Kayo Watanabe, Mina Nakauchi, Yoko Matsuzaki, Shinji Watanabe, Hideki Hasegawa, Yoshihiro Kawaoka   +20 more
doaj   +1 more source